baxter international inc (BAX*:Mexico)

Executive Profile*

Background*

Mr. Ludwig N. Hantson, Ph.D. has been President of Synovis Life Technologies Inc. since February 14, 2012. Mr. Hantson serves as President of International and Corporate Vice President of International at Baxter Healthcare Pty. Ltd. He oversees all international operations for Baxter as well as business development. He has been the Corporate Vice President for Baxter International Inc. since May 3, 2010 and also its President of BioScience since October 2010. He has ... been Chief Executive Officer of US and serves as Senior Vice President of Commercial Development and Specialty Businesses at Novartis Pharmaceuticals Corporation since April 2008 and December 2006 respectively. He oversees New Product Commercialization, Business Development & Licensing and Mature Products, and US Medical. He oversees the franchises for IDTI (Infectious Diseases, Transplant & Immunology) and Ophthalmics. He served as the President of International at Baxter International Inc. from May 3, 2010 to October 2010. Mr. Hantson served as the Chief Executive Officer of US of Novartis Corporation since April 2008. He served as Head of North American Pharmaceuticals of Novartis AG from April 2008 to April 2010 and served as its Chief Executive Officer of North American pharmaceuticals until April 2010. He served as the Chief Executive Officer of US of Novartis Pharmaceuticals Corporation since April 2008. He served as head of the specialty medicines unit in the United States. Mr. Hantson joined Novartis AG in 2001 and served as its Head of Global Early Commercial Development and later served as Head of the Global Neuroscience Business Franchise. He served as Head of Pharma Region Europe at Novartis AG. Before leading Region Europe, Mr. Hantson served as Head of Novartis Pharmaceuticals Canada, Inc., where he drove strong growth, increased market share, and led Novartis Pharma Canada to be named one of the Best Employers in Canada. Prior to joining Novartis, he spent 13 years at Johnson & Johnson (Janssen Pharmaceutica) in roles of increasing responsibility in the research and marketing areas. He has been Director at Synovis Life Technologies Inc. since February 14, 2012 and also serves as Director of Canada’s Research-Based Pharmaceutical Companies. He serves as a Director of Canada's Research-Based Pharmaceutical Companies. He received his Ph.D. in Motor Rehabilitation and Physical Therapy from the University of Louvain, Belgium.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
BAX*:MM	$899.70 MXN	+19.70

COMPETITOR COMPENSATION